articl
describ
epidemiolog
characterist
tropic
parasit
diseas
transmit
blood
andor
transplant
tabl
show
tropic
parasit
diseas
widespread
transmiss
epidem
activ
high
risk
infect
accord
region
diseas
associ
blood
andor
transplant
transmiss
highlight
bold
epidemiolog
tuberculosi
tb
major
caus
ill
death
worldwid
especi
asia
africa
accord
world
health
organ
estim
million
incid
case
rang
million
tb
global
equival
case
per
popul
estim
number
case
occur
asia
africa
smaller
proport
case
occur
eastern
mediterranean
region
european
region
region
america
india
alon
account
tb
case
worldwid
china
india
togeth
account
hiv
pandem
contribut
number
million
case
tb
report
hivposit
peopl
rate
cure
new
case
smearposit
tb
lower
among
hivposit
patient
among
hivneg
patient
transmiss
facilit
place
hiv
infect
tropic
parasit
infect
highli
preval
hivposit
tb
case
approxim
african
region
immunocompromis
host
includ
solid
organ
transplant
sot
hematopoiet
stem
cell
transplant
hsct
recipi
also
prone
reactiv
latent
mycobacterium
tuberculosi
infect
ltbi
tb
among
transplant
recipi
may
aris
reactiv
quiescent
foci
tuberculosi
transmiss
graft
contamin
activ
infect
person
risk
tb
transplant
recipi
estim
time
higher
gener
popul
even
develop
countri
mortal
rate
vari
report
tb
sot
recipi
especi
renal
transplant
preval
ltbi
among
renal
transplant
recipi
north
america
northern
europ
india
pakistan
reach
brazil
tb
number
one
among
neglect
tropic
diseas
transplant
incid
around
hsct
recipi
sot
recipi
reactiv
ltbi
account
tb
case
report
transplant
recipi
larg
reflect
local
incid
graft
transmiss
document
renal
lung
hepat
transplant
account
less
tb
case
transplant
recipi
one
intern
studi
tb
infect
recipi
consid
donor
deriv
recent
case
donorderiv
tb
result
infect
transplant
recipi
death
rais
discuss
regard
need
donor
tb
screen
new
blood
test
interferon
gamma
releas
assay
igra
diagnos
ltbi
pretranspl
evalu
epidemiolog
risk
tb
made
donor
recipi
countri
tb
highli
preval
howev
evalu
donor
elig
standard
assess
conduct
determin
potenti
donor
risk
previous
undiagnos
tb
ltbi
addit
select
laboratori
test
mention
begin
articl
donor
medic
record
review
specif
condit
includ
known
activ
tb
social
histori
obtain
close
rel
anoth
person
familiar
donor
chest
radiographi
perform
although
screen
process
might
reveal
symptom
risk
factor
tb
ltbi
investig
diagnost
test
requir
ltbi
also
evalu
tuberculin
skin
test
tst
delayedtyp
hypersensit
reaction
intracutan
inject
antigen
isol
cultur
filtrat
protein
precipit
live
donor
tst
result
interpret
posit
neg
accord
center
diseas
control
prevent
cdc
guidelin
gener
popul
howev
specif
tst
impair
donor
develop
countri
delayedtyp
hypersensit
reaction
may
indic
infect
nontubercul
mycobacteria
previou
vaccin
bcg
vaccin
live
attenu
mycobacteri
strain
deriv
mycobacterium
bovi
igra
specif
altern
interpret
accord
manufactur
instruct
ltbi
confirm
activ
tb
rule
treatment
ltbi
consid
organ
donat
especi
recent
seroconvert
organ
potenti
donor
whether
live
deceas
activ
tb
diseas
use
brucellosi
common
zoonot
diseas
caus
brucella
spp
mainli
infect
cattl
swine
goat
sheep
dog
transmit
peopl
via
direct
contact
livestock
drink
unpasteur
milk
infect
anim
human
brucella
caus
wide
rang
clinic
manifest
involv
variou
bodi
system
main
symptom
recurr
bout
high
temperatur
therefor
frequent
misdiagnos
drugresist
malaria
tropic
countri
case
brucellosi
report
renal
transplant
donorderiv
infect
hsct
endem
region
fever
anemia
pancytopenia
often
observ
may
mimic
sever
diseas
immunocompromis
patient
gener
diagnosi
made
detect
brucella
speci
blood
cultur
extens
investig
caus
consequ
complic
may
develop
case
delay
diagnosi
administr
appropri
antimicrobi
treatment
fluoroquinolon
doxycyclin
streptomycin
success
therapeut
option
recent
tigecyclin
demonstr
safe
effect
control
brucellosi
liver
transplant
malaria
acut
system
ill
caus
infect
plasmodium
falciparum
plasmodium
vivax
plasmodium
malaria
plasmodium
oval
billion
peopl
half
world
popul
risk
malaria
estim
million
episod
malaria
nearli
death
due
malaria
mostli
among
children
live
africa
peopl
live
poorest
countri
vulner
africa
everi
second
child
die
malaria
diseas
account
childhood
death
endem
malaria
case
report
central
south
america
subsaharan
africa
india
southeast
asia
part
oceania
awar
plasmodium
speci
endem
import
earli
introduct
appropri
treatment
p
falciparum
found
subsaharan
africa
southeast
asia
indian
subcontin
well
south
america
haiti
dominican
republ
jamaica
area
oceania
p
malaria
p
oval
present
subsaharan
africa
p
vivax
preval
area
southeast
asia
indian
subcontin
central
south
america
malaria
may
transmit
infect
blood
product
natur
exposur
plasmodiuminfect
mosquito
endem
region
via
infect
organ
tissu
contrast
larg
number
case
malaria
transmit
plasmodiuminfect
mosquito
worldwid
transmiss
blood
transfus
scarc
report
major
come
nonendem
countri
recent
publish
intern
forum
report
inform
tt
case
report
last
year
itali
brazil
unit
state
may
partial
explain
difficulti
distinguish
transmiss
transfus
vectorborn
case
endem
countri
anoth
aspect
malaria
may
harm
naiv
patient
expos
semiimmun
patient
recipi
blood
organ
nonendem
endem
region
respect
although
opportunist
diseas
malaria
relev
transplant
set
patient
either
histori
malaria
resid
endem
malaria
region
undergo
transplant
resid
endem
region
tropic
parasit
infect
consid
donor
recipi
expos
malaria
transplant
wash
organ
blood
transplant
procedur
may
enough
elimin
possibl
parasit
red
cell
within
organ
transmiss
may
occur
transfusionassoci
malaria
symptom
gener
develop
earlier
day
infect
transmit
infect
cell
within
organ
week
plasmodium
speci
capabl
surviv
hour
blood
c
therefor
cold
preserv
time
gener
enough
prevent
transmiss
especi
heart
liver
transplant
requir
shorter
cold
preserv
time
hour
heart
hour
liver
kidney
transplant
hour
report
malaria
case
multiorgan
donat
support
hypothesi
graft
sourc
plasmodium
transplant
recipi
screen
prevent
investig
epidemiolog
risk
malaria
mandatori
blood
transplant
donor
recipi
endem
region
possibl
routin
serolog
blood
smear
test
consid
individu
exposur
risk
develop
countri
past
histori
malaria
contraind
organ
stem
cell
donat
clinician
must
awar
malaria
alway
follow
typic
paroxysm
cyclic
pattern
transplant
recipi
high
index
suspicion
maintain
care
patient
identifi
risk
factor
donor
recipi
histori
mosquito
exposur
region
p
vivax
p
oval
infect
clinician
bear
mind
parasit
exoerythrocyt
schizogoni
liver
make
erad
difficult
dormant
hypnozoit
form
caus
relaps
month
later
guidelin
develop
countri
recommend
donor
nonendem
area
travel
area
malaria
transmiss
occur
defer
donat
month
return
similarli
person
live
live
malaria
area
defer
year
deferr
time
possibl
maintain
donor
receiv
empir
treatment
malaria
donat
blood
smear
immunochromatogen
test
polymeras
chain
reaction
pcr
inappropri
test
evalu
asymptomat
potenti
donor
chaga
diseas
american
trypanosomiasi
chaga
diseas
caus
cruzi
protozoan
parasit
first
describ
carlo
chaga
chaga
diseas
endem
america
south
unit
state
south
latin
america
consequ
initi
south
central
american
countri
sinc
control
chaga
transmiss
diseas
preval
reduc
estim
million
peopl
infect
million
peopl
parasit
gener
transmit
fece
infect
triatomin
insect
penetr
parasit
bite
wound
conjunctiva
mucou
membran
transmiss
also
occur
organ
transplant
blood
transfus
mother
child
pregnanc
laboratori
incid
recent
outbreak
due
ingest
contamin
food
drink
report
transmiss
blood
product
blood
transmiss
consid
second
import
method
acquir
chaga
diseas
except
blood
deriv
blood
compon
infect
transmiss
blood
transfus
first
suggest
mazza
argentina
first
case
transfusionassoci
chaga
diseas
publish
true
number
report
case
also
underestim
case
publish
nonendem
countri
case
transfusionassoci
transmiss
go
undetect
acut
infect
often
asymptomat
level
awar
chaga
diseas
among
clinician
low
endem
countri
mandatori
screen
test
implement
sinc
residu
risk
infect
calcul
around
unit
transplant
recipi
nonendem
countri
like
acquir
cruzi
infect
blood
transfus
infect
graft
wherea
infect
recipi
endem
region
risk
reactiv
latent
infect
immunosuppress
million
individu
infect
cruzi
endem
countri
first
strong
evid
transmiss
via
graft
report
brazil
four
renal
transplant
recipi
develop
chaga
diseas
receiv
graft
infect
donor
chronic
phase
cruzi
infect
seri
publish
mostli
argentina
brazil
unit
state
case
cruzi
transmiss
via
graft
report
cdc
three
sot
recipi
liver
kidney
receiv
organ
donor
develop
chaga
diseas
two
case
report
heart
transplant
recipi
case
investig
sourc
infect
show
blood
donor
test
seroneg
cruzi
wherea
organ
donor
test
seroposit
serolog
screen
donor
routin
highli
preval
countri
posit
result
differ
serolog
test
necessari
consid
patient
infect
hemagglutin
assay
use
screen
method
past
replac
eia
standard
donor
screen
donorrecipi
pretranspl
investig
epidemiolog
risk
chaga
diseas
mandatori
risk
factor
cruzi
infect
part
nativ
popul
endem
area
continent
countri
latin
america
receiv
blood
transfus
endem
countri
born
mother
nativ
endem
area
unknown
serolog
chaga
diseas
live
endem
area
month
eia
cruzi
recommend
case
posit
test
result
donor
die
acut
chaga
diseas
exclud
case
cardiac
transplant
heart
patient
chronic
chaga
diseas
contraind
risk
chagas
myocard
similarli
use
intestin
donor
chaga
diseas
contraind
latin
america
donor
chronic
infect
cruzi
exclud
donat
organ
except
heart
intestin
howev
close
followup
serolog
parasitolog
method
strongli
recommend
immedi
treatment
benznidazol
day
nifurtimox
day
start
parasitemia
detect
pretranspl
treatment
infect
live
donor
benznidazol
may
consid
base
experi
south
america
chaga
transplant
work
group
unit
state
consid
kidney
liver
cruziinfect
donor
transplant
inform
consent
recipi
follow
close
monitor
surveil
includ
pretranspl
parasitolog
studi
quantit
pcr
strout
method
direct
parasitolog
test
weekli
day
bimonthli
day
annual
thereaft
recommend
prophylaxi
controversi
cardiac
transplant
recipi
prophylact
treatment
prevent
diseas
reactiv
consid
patient
chagas
cardiomyopathi
undergo
cardiac
transplant
healthi
donor
transplant
recipi
earli
treatment
start
monitor
show
evid
reactiv
leishmaniasi
primarili
zoonot
infect
includ
anim
reservoir
host
transmiss
cycl
anthroponot
form
leishmaniasi
increasingli
observ
human
enter
transmiss
cycl
parasit
get
infect
anthroponot
form
man
sole
sourc
infect
vector
protozoan
transmit
human
bite
infect
femal
mosquito
genu
phlebotomu
old
world
lutzomyia
new
world
howev
incident
transmiss
blood
transfus
needl
share
among
intraven
drug
addict
also
describ
leishmaniasi
preval
contin
consid
endem
countri
develop
countri
viscer
leishmaniasi
vl
case
occur
bangladesh
brazil
india
nepal
sudan
mucocutan
leishmaniasi
case
occur
bolivia
brazil
peru
cutan
leishmaniasi
case
occur
afghanistan
brazil
iran
peru
saudi
arabia
syria
estim
million
peopl
worldwid
present
infect
million
estim
new
case
occur
everi
year
transmiss
blood
product
tt
vl
clinic
featur
outcom
similar
natur
infect
describ
endem
nonendem
area
recent
studi
leishmania
dna
found
asymptomat
blood
donor
test
posit
antileishmania
antibodi
therefor
theoret
risk
tt
vl
present
case
leishmaniasi
describ
transplant
recipi
vl
frequent
observ
clinic
present
case
occur
sot
recipi
mainli
kidney
liver
case
report
hsct
recipi
geograph
distribut
leishmaniasi
case
among
transplant
recipi
reflect
endem
area
human
leishmaniasi
diseas
number
transplant
perform
twothird
report
case
spain
itali
franc
transplant
recipi
leishmaniasi
may
occur
due
reactiv
latent
infect
previous
infect
recipi
due
de
novo
infect
transplant
recipi
live
travel
area
endem
blood
transfus
via
infect
graft
rout
transmiss
rare
like
occur
organ
form
part
reticuloendotheli
system
liver
present
routin
serolog
screen
organ
donor
endem
countri
recommend
donor
known
posit
leishmaniasi
monitor
recipi
posttranspl
period
advis
suspect
case
serolog
test
direct
detect
leishmania
amastigot
bone
marrow
biopsi
sampl
perform
fluoresc
antibodi
techniqu
enzymelink
immunosorb
assay
use
western
blot
confirm
epidemiolog
hiv
zoonosi
origin
simian
virus
transmit
man
probabl
begin
twentieth
centuri
africa
urban
favor
adapt
virus
human
host
sexual
transmiss
main
rout
spread
africa
hiv
reach
sever
countri
includ
unit
state
first
aid
case
describ
estim
approxim
million
person
infect
worldwid
major
africa
respons
case
present
countri
transmiss
blood
transfus
becam
evid
larg
number
infect
individu
among
person
expos
blood
product
unit
state
risk
decreas
unit
test
avail
unit
nat
introduc
thousand
tt
case
occur
worldwid
incid
aidsrel
mortal
dramat
affect
patient
demand
multipl
transfus
constant
use
plasma
product
hemophilia
fear
tt
hiv
infect
enorm
impact
societi
drive
forc
led
current
level
safeti
achiev
mani
technolog
develop
massiv
invest
blood
industri
first
report
hiv
infect
transmit
organ
transplant
case
extens
document
forc
donor
test
mandatori
countri
sinc
laboratori
screen
hiv
infect
becam
avail
case
hiv
transmiss
organ
transplant
document
unit
state
emphas
success
initi
fourthgener
antibodi
test
abl
detect
antihiv
antibodi
presenc
capsid
antigen
conjug
format
provid
high
degre
safeti
organ
avail
transplant
howev
requir
obtain
plasma
serum
donor
may
possibl
cadaver
donor
singl
organ
donor
may
infect
sever
recipi
guidelin
strongli
recommend
use
organ
exclus
neg
donor
nat
also
contribut
reduc
window
period
increas
protect
transplant
recipi
introduct
nat
risk
tt
hbv
hcv
hiv
unit
state
respect
nevertheless
addit
yield
obtain
nat
fourth
eia
minim
becom
signific
region
hiv
preval
incid
high
south
africa
howev
risk
transmiss
organ
transplant
must
balanc
risk
recipi
die
wait
organ
due
organ
shortag
organ
transplant
often
lifesav
organ
donor
elev
risk
hiv
infect
may
accept
inform
consent
recipi
whenev
benefit
transplant
consid
outweigh
risk
potenti
diseas
transmiss
recipi
organ
increasedrisk
donor
recommend
undergo
test
month
transplant
hbv
small
dna
viru
effici
transmiss
blood
sexual
contact
preval
global
estim
million
carrier
infect
adult
rel
harmless
expos
popul
clear
without
symptom
becom
chronic
infect
may
lead
liver
inflamm
cirrhosi
hepatocellular
carcinoma
vaccin
develop
introduc
led
reduct
preval
infect
among
vaccine
observ
nowaday
vacine
becom
young
adult
sexual
expos
howev
liver
failur
caus
hbv
still
import
indic
transplant
introduct
hbsag
test
blood
donor
tt
hbv
observ
approxim
patient
multipl
transfus
improv
test
introduct
antihbc
test
significantli
decreas
rate
howev
hbv
still
frequent
transmit
viral
infect
sever
case
transmiss
continu
report
countri
low
high
endem
may
aggress
cours
immunocompromis
host
hbv
transmiss
report
transplant
organ
kidney
liver
also
cornea
bone
marrow
presenc
hbv
import
indic
liver
transplant
certain
circumst
difficult
distinguish
new
infect
liver
graft
reactiv
recipi
previou
infect
without
prophylaxi
almost
case
hbvinfect
recipi
present
recurr
transplant
avail
hightit
antihepat
b
surfac
immunoglobulin
oral
antivir
drug
lamivudin
greatli
reduc
incid
hbvrelat
posttransplant
morbid
antihbc
marker
exposur
wherea
hbsag
marker
viru
replic
preclud
donat
blood
organ
donor
reactiv
latter
due
organ
scarciti
accept
transplant
organ
donor
recipi
reactiv
antihbc
center
hbsagposit
organ
transplant
recipi
antihbsag
titer
consid
protect
iul
howev
situat
associ
wors
prognosi
frequent
reactiv
hbv
lead
graft
loss
endem
countri
itali
greec
china
taiwan
blood
donor
screen
hbsag
test
preval
high
antihbc
titer
would
consider
affect
pool
avail
donor
countri
unit
state
germani
brazil
use
hbv
marker
screen
recent
nat
extend
hbvdna
incorpor
multiplex
format
hcv
hiv
nat
platform
nat
identifi
donor
hbv
window
period
also
interdict
donat
regard
occult
b
infect
obi
thu
deem
individu
neg
hbsag
harbor
hbvdna
potenti
infecti
obi
common
area
hbv
endem
respons
transfusion
case
verifi
introduct
nat
current
risk
tt
hbv
unit
state
parallel
test
perform
nat
antihbc
hbsag
estim
greater
whenev
possibl
nat
organ
donor
accomplish
group
usual
present
higher
risk
infecti
marker
hepat
c
epidemiolog
hcv
rna
viru
belong
flavivirida
famili
transmit
contact
blood
contrast
member
flavivirida
famili
hcv
transmiss
human
arthropod
vector
never
report
hcv
first
clone
plasma
individu
experienc
posttransfus
hepat
associ
hepatit
virus
hav
hbv
hcv
clone
character
laboratori
tool
identif
infect
patient
rapidli
develop
use
epidemiolog
studi
screen
blood
organ
donor
estim
approxim
world
popul
carrier
hcv
populationbas
survey
shown
true
preval
unit
state
egypt
highest
preval
attribut
massiv
spread
viru
campaign
treatment
schistosomiasi
along
nile
river
transmiss
blood
product
hcv
identifi
search
caus
hepat
frequent
observ
transfus
recipi
hbv
hav
infect
rule
laboratori
test
antihcv
test
made
avail
socal
nona
nonb
hepat
incid
greater
patient
multipl
transfus
nowaday
risk
transfus
unit
nat
antibodi
test
perform
date
hcv
main
caus
failur
kidney
transplant
use
organ
hcvposit
donor
accept
common
mainli
kidney
recipi
whose
antihcv
test
result
also
posit
howev
hcv
hiv
cotransmiss
also
observ
hcvneg
recipi
presum
donor
window
period
although
use
nat
could
prevent
case
use
recommend
may
caus
delay
transplant
increas
organ
shortag
strongli
contrast
polici
blood
transfus
detect
antibodi
sever
hcv
antigen
eia
format
test
choic
screen
blood
organ
donor
present
eia
fourth
gener
similar
antihiv
assay
allow
simultan
detect
antibodi
hcv
core
antigen
difficulti
associ
exclud
donor
risk
hcv
infect
predon
interview
infect
donor
report
obviou
sourc
transmiss
eg
use
intraven
drug
previou
transfus
needl
share
henc
prevent
tt
hcv
infect
larg
reli
laboratori
test
longer
time
seroconvers
approxim
day
hcv
first
agent
target
nat
yield
natonli
donor
worldwid
donat
import
region
variat
arbovirus
heterogen
group
agent
transmit
human
arthropod
significantli
mosquito
tick
feed
human
blood
sever
speci
femal
mosquito
transmit
pathogen
present
digest
system
individu
blood
suck
aed
aegypti
aed
albopictu
adapt
live
close
human
reproduc
water
accumul
tropic
parasit
infect
near
human
habitat
spread
worldwid
dengu
import
humanarthropodborn
viral
diseas
autochthon
case
describ
unit
state
florida
argentina
vaccin
avail
present
incid
estim
million
case
global
rise
everi
year
mainli
america
dengu
serotyp
infect
one
serotyp
provid
lifelong
immun
serotyp
partial
transient
protect
subsequ
infect
serotyp
compel
evid
secondari
tertiari
dengu
infect
tend
sever
primari
dengu
infect
bitten
infect
mosquito
symptom
develop
approxim
day
last
maximum
day
contrast
huge
number
case
dengu
fever
endem
countri
rare
report
transfusiontransmit
dengu
astonish
welldocu
episod
dengu
viru
transmiss
blood
transfus
result
clinic
evid
diseas
dengu
hemorrhag
fever
recipi
report
far
much
less
would
expect
preval
project
blood
donor
although
transient
asymptomat
dengu
viremia
potenti
risk
blood
suppli
recent
public
dengu
viremia
detect
asymptomat
blood
donor
brazil
hondura
respect
recipi
systemat
investig
detect
transfusionorgan
transmiss
occur
present
overt
symptom
studi
need
establish
rate
tt
virem
donat
clinic
consequ
recipi
transmiss
dengu
transplant
recipi
live
travel
endem
area
far
via
mosquito
bite
publish
case
dengu
acquir
vector
transmiss
dengu
transmiss
via
graft
also
report
hsct
renal
transplant
recipi
diseas
certainli
underdiagnos
transplant
popul
endem
area
case
mild
present
flulik
syndrom
consequ
actual
incid
morbid
mortal
associ
dengu
complic
difficult
estim
patient
dengu
elig
blood
organ
donat
recoveri
develop
igm
igg
indic
viru
clearanc
risk
transmiss
blood
organ
donat
stem
asymptomat
host
short
incub
period
preced
viremiafev
observ
case
dengu
fever
asymptomat
infect
case
unexpectedli
dengu
rna
detect
among
blood
donor
endem
area
far
screen
test
valid
blood
organ
donat
test
strategi
analog
wnv
belong
flavivirida
famili
includ
nat
antigen
assay
high
sensit
rabi
zoonot
viral
diseas
infect
domest
wild
anim
distribut
worldwid
countri
free
rabi
japan
new
zealand
sweden
norway
greec
portug
barbado
fiji
seychel
maldiv
uruguay
chile
rabi
preval
develop
countri
certainli
underreport
sever
countri
consid
endem
canin
rabi
among
india
pakistan
includ
rabi
among
notifi
diseas
henc
actual
incid
unknown
dog
bite
frequent
mode
transmiss
countri
africa
asia
latin
america
middl
east
contrast
north
america
document
human
rabi
death
occur
result
infect
bat
rabi
viru
contact
infect
saliva
scratch
lick
broken
skin
mucou
membran
may
also
caus
rabi
humantohuman
transmiss
occur
almost
exclus
result
organ
tissu
transplant
rabi
viru
caus
acut
viral
encephalomyel
virtual
fatal
viru
may
remain
latent
near
inocul
site
replic
muscl
dermal
cell
case
bat
variant
around
rabi
death
occur
annual
gener
associ
dog
bite
bat
rabi
variant
may
caus
clinic
manifest
differ
seen
human
infect
canin
rabi
humantohuman
transmiss
rabi
occur
organ
tissu
transplant
recipi
cornea
solid
organ
vascular
tissu
case
occur
countri
unit
state
germani
thailand
india
iran
franc
case
donor
die
ill
compat
rabi
even
though
diagnosi
suspect
recipi
die
rabi
case
illustr
easili
diagnosi
rabi
may
miss
clear
investig
rabi
exposur
done
sot
case
donor
recent
histori
bat
dog
bite
elicit
consid
import
bat
teeth
fine
bat
bite
batinflict
scratch
mark
may
undetect
epidemiolog
risk
underestim
unit
state
canada
incid
batvari
rabi
case
increas
case
per
billion
personyear
case
per
billion
personyear
detail
histori
contact
bat
obtain
organ
donor
rel
friend
absenc
clear
histori
physic
sign
reliabl
perform
rabi
diagnost
test
safest
strategi
exclud
donor
neurolog
sign
symptom
unknown
caus
case
exposur
suspect
histori
rabi
diagnos
postmortem
donor
postexposur
prophylaxi
human
rabi
immunoglobulin
immedi
start
iukg
well
first
dose
rabi
vaccin
addit
dose
administ
day
first
dose
vaccin
alway
administ
intramuscularli
deltoid
area
adult
anterolater
aspect
thigh
children
previou
centuri
discoveri
success
introduct
penicillin
develop
antibiot
therapi
led
medic
commun
predict
infecti
diseas
would
declin
lead
caus
death
worldwid
give
place
cancer
circulatori
ill
surprisingli
infecti
diseas
mainli
malaria
continu
kill
thousand
affect
million
around
world
chaotic
urban
wast
accumul
global
warm
tourism
human
migrat
contribut
dissemin
infecti
agent
associ
vector
autochthon
dengu
case
unit
state
franc
chikungunya
outbreak
itali
illustr
new
scenario
diseas
previous
name
tropic
long
relianc
human
donor
blood
tissu
transplant
continu
issu
transmiss
agent
fact
sever
agent
restrict
tropic
dealt
technolog
advanc
molecular
diagnost
vaccin
product
provid
tool
activ
surveil
quick
respons
seen
recent
sever
acut
respiratori
syndrom
influenza
threat
appropri
measur
avoid
potenti
pandem
lethal
agent
perman
research
activ
commun
effect
answer
author
hope
give
small
contribut
articl
